PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 17, 2014, Pages 6395-6400

  Schmit, Fabienne ^a,b   Utermark, Tamara ^a,b,c   Zhang, Sen ^a,b,d   Wang, Qi ^a   Von, Thanh ^a,b   Roberts, Thomas M ^a,b   Zhao, Jean J ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MERRIMACK PHARMACEUTICALS   (United States)

^d ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

Genetically engineered mouse model; Ovarian cancer; PI3K inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; BYL 719; CYTOKERATIN; CYTOKERATIN 8; ESTROGEN RECEPTOR; KI 67 ANTIGEN; KIN 193; KRAS PROTEIN; PHOSPHATIDYLINOSITIDE 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN P110; PROTEIN P53; PROTEIN S6; TRP53 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE MUTATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

GENETICALLY ENGINEERED MOUSE MODEL; OVARIAN CANCER; PI3K INHIBITORS;

ANIMALS; CARCINOGENESIS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MICE; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS P21(RAS); PTEN PHOSPHOHYDROLASE; RATS;

EID: 84899639748     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1323004111     Document Type: Article

References (48)

1. Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7(8):606-619.
2. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11(5):329-341.
3. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8(8):627-644.
4. Chang HW, et al. (1997) Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 276(5320):1848-1850.
5. Zhao JJ, et al. (2003) Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell 3(5):483-495.
6. Zhao JJ, et al. (2005) The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 102(51):18443-18448.
7. Song MS, Salmena L, Pandolfi PP (2012) The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13(5):283-296.
8. Samuels Y, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670):554.
9. Bader AG, Kang S, Zhao L, Vogt PK (2005) Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5(12):921-929.
10. Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: Variations on a theme. Oncogene 27(41):5497-5510.
11. Thomas RK, et al. (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39(3):347-351.
12. Wood LD, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318(5853):1108-1113.
13. Boller D, et al. (2008) Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells. Clin Cancer Res 14(4):1172-1181.
14. Liu Z, et al. (2008) Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93(8): 3106-3116.
15. Graupera M, et al. (2008) Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 453(7195):662-666.
16. Utermark T, et al. (2012) The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev 26(14):1573-1586.
17. Zhao JJ, et al. (2006) The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci USA 103(44): 16296-16300.
18. Gupta S, et al. (2007) Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129(5):957-968.
19. Ramjaun AR, Downward J (2007) Ras and phosphoinositide 3-kinase: Partners in development and tumorigenesis. Cell Cycle 6(23):2902-2905.
20. Fritsch R, et al. (2013) RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell 153(5):1050-1063.
21. Hecht JL, Mutter GL (2006) Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 24(29):4783-4791.
22. Jia S, et al. (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454(7205):776-779.
23. Ni J, et al. (2012) Functional characterization of an isoform-selective inhibitor of PI3Kp110β as a potential anticancer agent. Cancer Discov 2(5):425-433.
24. Torbett NE, et al. (2008) A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J 415(1):97-110.
25. Wee S, et al. (2008) PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci USA 105(35):13057-13062.
26. Berenjeno IM, et al. (2012) Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. Biochem J 442(1):151-159.
27. Jia S, et al. (2013) Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov 3(1):44-51.
28. Wang Q, et al. (2013) Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome. Genes Dev 27(14): 1568-1580.
29. Smolle E, et al. (2013) Targeting signaling pathways in epithelial ovarian cancer. Int J Mol Sci 14(5):9536-9555.
30. Dinulescu DM, et al. (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11(1):63-70.
31. Jackson EL, et al. (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15(24):3243-3248.
32. Tuveson DA, et al. (2004) Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5(4):375-387.
33. Rodon J, Dienstmann R, Serra V, Tabernero J (2013) Development of PI3K inhibitors: Lessons learned from early clinical trials. Nat Rev Clin Oncol 10(3):143-153.
34. Furet P, et al. (2013) Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett 23(13):3741-3748.
35. Ciraolo E, et al. (2010) Essential role of the p110beta subunit of phosphoinositide 3-OH kinase in male fertility. Mol Biol Cell 21(5):704-711.
36. Guillermet-Guibert J, et al. (2008) The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci USA 105(24):8292-8297.
37. Martin V, et al. (2010) Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood 115(10):2008-2013.
38. Dbouk HA, Pang H, Fiser A, Backer JM (2010) A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci USA 107(46):19897-19902.
39. Knight ZA, et al. (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125(4):733-747.
40. Vogt PK (2011) PI3K p110β: More tightly controlled or constitutively active? Mol Cell 41(5):499-501.
41. Castellano E, Downward J (2010) Role of RAS in the regulation of PI 3-kinase. Curr Top Microbiol Immunol 346:143-169.
42. Ebi H, et al. (2011) Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest 121(11):4311-4321.
43. Molina-Arcas M, Hancock DC, Sheridan C, Kumar MS, Downward J (2013) Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRASmutant lung cancer. Cancer Discov 3(5):548-563.
44. Kinross KM, et al. (2012) An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest 122(2):553-557.
45. Wu R, et al. (2007) Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 11(4):321-333.
46. Jia S, Roberts TM, Zhao JJ (2009) Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol 21(2):199-208.
47. Castillo JJ, Furman M, Winer ES (2012) CAL-101: A phosphatidylinositol-3- kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs 21(1):15-22.
48. Oda K, et al. (2008) PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res 68(19):8127-8136.